Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Breast

A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients with Recurrent Brain Metastases

The main purpose of this research study is to find out if the study drug, ANG1005 can shrink tumor cells that have spread to the brain. Another purpose of this study is to evaluate the safety, effectiveness and how ANG1005 is being tolerated by patients with brain metastases.

Status: Accepting New Patients
Principal Investigator: Kumthekar

A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)

The purpose of this study is to see if adding veliparib and/or carboplatin to standard neoadjuvant chemotherapy can help shrink triple negative breast cancer (TNBC) faster, and lower the risk of the cancer coming back in other parts of the body.

Status: Accepting New Patients
Principal Investigator: Gradishar

A Phase I Study of BYL719 and Trastuzumab-MCC-DM1 in HER2-Positive Metastatic Breast Cancer Patients with Progression on Prior Trastuzumab and Taxane-Based Therapy

The purpose of this study is to see whether a combination of two different drugs - trastuzumab-MCC-DM1 (T-DM1) and BYL719 is safe, and if it might be effective in treating metastatic breast cancer.

Status: Accepting New Patients
Principal Investigator: Jain

An Open-Label, Phase I, Dose-Escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate Bay 1187982 in Subjects with Advanced Solid Tumors Known to Express FGFR2

The purpose of this study is to evaluate the safety, tolerability (the effect of the study drug on the body), of BAY 1187982 when given as a single agent in patients with advance or refractory (has not responded to other treatment) solid tumors.

Status: Accepting New Patients
Principal Investigator: Kalyan

REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology

The purpose of this study is to test an 8-week stress reduction course that is intended to reduce anxiety and improve the quality of life of adolescents and young adults diagnosed with cancer. This study will include a total of 100 participants, all of whom have been diagnosed with cancer.

Status: Accepting New Patients
Principal Investigator: Victorson

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Dokucu

Phase II trial of EVEROLIMUS ± Trastuzumab in hormone-refractory metastatic breast cancer

The purpose of this study is to investigate if trastuzumab or everolimus is effective for breast cancers that are no longer controlled with (resistant to) hormonal therapies, and have small to moderate amounts of HER2/neu.

Status: Accepting New Patients
Principal Investigator: Santa-Maria

A Study Of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients with Her2+ Metastatic Breast Cancer Who Have Received Two or More Prior Her2-Directed Regimens in the Metastatic Setting (NALA)

The purpose of this study is to test the safety and benefit of an experimental drug called neratinib, when given with an approved breast cancer drug called capecitabine.

Status: Accepting New Patients
Principal Investigator: Gradishar

Hippocampal Predictors of Cognitive Impairment (HippoPCI) in Breast Cancer Patients

The purpose of this study is to improve our understanding of differences in size, shape and activity of a variety of brain areas that can occur in women with breast cancer undergoing adjuvant chemotherapy or hormonal therapy, and how these brain areas are related to the development of mild mental impairment as the results of these treatments. This study involves obtaining pictures of the brain’s size, shape and activity using a Magnetic Resonance Imaging (MRI) device, a machine that uses a powerful magnet to obtain this information without using any radiation. This procedure has been used safely with humans in many different studies.

Status: Accepting New Patients
Principal Investigator: Wang

Modular phase II study to link targeted therapy to patients with pathway activated tumors:Module 6 – BGJ398 for patients with tumors with FGFR genetic alterations

Researchers want to know if BGJ398 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a FGFR regulated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Chae

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Chae

A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination with Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects with Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas

The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given alone or in combination with tremelimumab, MEDI4736, or rituximab in subjects with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL).

Status: Accepting New Patients
Principal Investigator: Chae

A Phase 2, Randomized, Open-Label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients with FGF Aberrant Metastatic Breast Cancer

The purpose of this clinical trial is to to look at the effects, good and/or bad, of lucitanib on patients with breast cancer.

Status: Accepting New Patients
Principal Investigator: Gradishar

Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer

The purpose of this research study is to determine a safe dose of the drug Trastuzumab and then determine how effective this treatment is.

Status: Accepting New Patients
Principal Investigator: Raizer

A Pilot Study of Time Restricted Diet in Obese/Overweight Pre & Postmenopausal Women

The purpose of this study is to study the relationships between obesity, hormones and menopausal status, and breast cancer.

Status: Accepting New Patients
Principal Investigator: Khan

Improving Quality of Life among Hispanic/Latino Breast, Colorectal & Prostate Cancer Survivors: A Randomized Control Trial of Patient Navigators Using the LIVESTRONG Cancer Navigation Services Program

The purpose of this study is to compare patient navigation with or without the addition of LIVESTRONG navigation services.

Status: Accepting New Patients
Principal Investigator: Penedo

Targeted eHealth Intervention to Reduce Fear of Recurrence (FoR) Among Cancer Survivors: FoRtitude

The purpose of this study is to create a web-based application titled FoRtitude that teaches breast cancer survivors how to reduce their fear of cancer recurrence.

Status: Accepting New Patients
Principal Investigator: Penedo

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Petrich

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Hitsman

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Status: Accepting New Patients
Principal Investigator: Kalapurakal

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

The main purpose of this clinical trial is to study patients with positive nodes before chemotherapy who become negative after chemotherapy to see1) if, after lumpectomy (surgery to remove cancer), radiation to the breast and lymph nodes will be better than radiation only to the breast at keeping cancer from returning, and 2) if, after mastectomy (surgery to remove part or all of one or both breasts), radiation to the area where the breast used to be and to the lymph nodes is better than no radiation at keeping cancer from returning.

Status: Accepting New Patients
Principal Investigator: Donnelly

Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

The purpose of this study is to determine if a natural compound derived from flaxseed (Brevail) can reduce breast cell growth in premenopausal women. Also, to see if women at increased risk for breast cancer are likely to tolerate SDG daily for 12 months without significant side effects or changes in their menstrual cycles.

Status: Accepting New Patients
Principal Investigator: Khan

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes,Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

The purpose of this study is to find out if the Oncotype DX Recurrence Score can help decide whether patients should receive chemotherapy or not.

Status: Accepting New Patients
Principal Investigator: Gradishar

SWOG 1207: Phase-III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study - evaluating everolimus with endocrine therapy

The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without your cancer returning.

Status: Accepting New Patients
Principal Investigator: Jain

A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy

The purpose of this study is to see what effect bevacizumab, the drug being tested, will have on brain disease from solid tumor cancers. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.

Status: Accepting New Patients
Principal Investigator: Kumthekar

last updated: Mon - July 27, 2015 - 08:11 AM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.